+441518081136Necroptosis is a programmed death pathway involving in pituitary adenoma tumorgenesis
International Conference on Oncology & Cancer Therapy
March 18-19, 2019 | London, UK
Alireza Sheikhi
Iran University of Medical Sciences, Iran
Scientific Tracks Abstracts : J Med Oncl Ther
Abstract:
Introduction: Pituitary adenomas impose burden of morbidity
due to hormone hyper secretion and related effects on
patients. Molecular mechanism underlying its incidence,
development and progression have yet to be elucidated which
can provide insights into new and more efficient therapeutic
approaches. The involvement of necroptosis as an appealing
way of cell death in pathogenesis of pituitary adenomas is
perused in the current study.br/>
Methods: The expression level of necroptosis crucial mediators
(RIP1K, RIP3K, and MLKL) was assessed via Real-Time PCR in
tumor tissues of prevalent functional and non-functional pituitary
adenoma and normal Pituitary tissues. The effect of Shikonin on
the cell viability and induction of apoptosis or necrosis in the
presence and absence of necroptosis inhibitor (Necrostatin-1)
were evaluated in pituitary adenoma cell line (GH3).br/>
Results: Our results revealed that RIP1K expression level
was increased in tumor tissues of different types of pituitary
adenomas which was associated with significant decrease in the
expression level of RIP3K and MLKL in tumor tissues comparing
to normal pituitary. Shikonin reduced the percentage of GH3
viable cells in a dose dependent manner which was associated
with the induction of apoptosis and necrosis. The Shikonininduced
cell death was diminished in response to suppression
of necroptosis.br/>
Conclusion: Necroptosis pathway is involved in the regulation
of pituitary tumor cell proliferation. Suppression of necroptosis
resulted in an accelerated cell proliferation which can cause
pituitary tumor formation. Therefore, necroptosis biomarkers
can be perused as hallmark mediators and the necroptosis
pathway activation can be targeted as a therapeutic solution
in management of pituitary tumors.
Biography:
Alireza Sheikhi is the manager of the BioChem lab and senior scientist in Armenia (clinical lab and cancer research).
E-mail: alireza.sheikhi71@yahoo.com
PDF HTML